Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Amgen and Arrotex Partner to Promote Prolia® (denosumab) in Australia

May 7, 2024

On 7 May 2024, Pharma In Focus reported that Arrotex has partnered with Amgen to promote Amgen’s Prolia® (denosumab) in Australia.  It is planned that the partnership “will support the future growth of Prolia in the Australian market, utilising the infrastructure and reach of Arrotex to further the patient, pharmacist and prescriber experience”.  It is unclear when the agreement will take effect.

There are no Prolia® (denosumab) biosimilars approved in Australia to date.  Prolia® biosimilars have been approved in the US (Sandoz’s Jubbonti®, March 2024), Canada (Jubbonti®, February 2024) and China (Boan Biotech’s Byoubei® (November 2022) and Mabwell’s Mailishu® (March 2023)).